MedTrace Logo

A Morbidity-Mortality and Remodeling Study With Valsartan

NCT00133328 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3000

Last updated 2005-10-28

No results posted yet for this study

Summary

The JIKEI HEART Study has been designed to investigate whether concomitant treatment with valsartan, an angiotensin II receptor blocker (ARB), in addition to conventional treatment, will improve the prognosis of 3000 Japanese patients with cardiovascular diseases.

Conditions

  • Hypertension
  • Ischemic Heart Disease
  • Congestive Heart Failure

Interventions

DRUG

valsartan

Sponsors & Collaborators

  • Jikei University School of Medicine

    lead OTHER

Principal Investigators

  • Seibu Mochizuki, MD., PhD · The Jikei University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Completion
2005-11-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00133328 on ClinicalTrials.gov